Abstract 281P
Background
Based on Globocan 2020, prostate cancer is the second most common male cancer worldwide. One of the main treatments for localized prostate cancer patients is definitive radiotherapy. Regarding limited access to intensity modulated radiation therapy and other modern techniques in developing countries, most patients in these countries are still being treated with 3D conformal RT techniques. Considering the fact that there is association between local control and prostate cancer specific mortality, we aimed to investigate the local control in unfavorable intermediate and high risk prostate cancer patients whom underwent definitive radiotherapy with 3D conformal technique.
Methods
50 patients involved in this study. They all were treated by definitive radiotherapy with 3D conformal technique since 2014 in the Radiation Department of Hamadan University of Medical Sciences. The required data was collected through the assessment of patient's' medical records. All patients were treated using a 4-field (Box) 3D technique with a total dose of 70 Gy. Additionally, in all patients, the whole pelvis was covered in the initial phase of treatment (46Gy).
Results
After the median follow up of 45 month 13 treatment failure was seen in the study population. Bio-chemical relapse occurred in 13 patients (26%). Seven patients were found to have local recurrences (14%). Distant failure, all in bone, occurred in 6 patients (12%). The 3year BCR free survival, local failure free survival and metastases free survival were 76%, 88%, and 88% respectively. The most important factor for BCR, distant failure, and overall failure was extension of disease (T stage).
Conclusions
Our results were lower compared to the results announced in the developed countries' center. This indicates that the use of modern radiotherapy techniques has been essential in prostate cancer treatment, both due to the increased treatment effectiveness and the reduction of treatment side effects. It is vital for developing countries to plan their health care policies in a way that improves patients' access to these innovative techniques. And governments should allocate a budget for updating radiotherapy devices in their country's infrastructure planning.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
R. Bayani.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
111P - Comparison of the efficacy and safety of fruquintinib and fruquintinib combined with immune checkpoint inhibitors in the treatment of metastatic microsatellite stable colorectal cancer: A real-world study
Presenter: Zhiqiang Wang
Session: Poster Display
Resources:
Abstract
112P - Optimal classification and treatment strategy based on technical and oncological futures in recurrence of colorectal liver metastases
Presenter: Kosuke Kobayashi
Session: Poster Display
Resources:
Abstract
113P - Phase I/II study of capecitabine(C)/oxaliplatin(O)/irinotecan(I) combined with bevacizumab(B) in the first-line treatment of metastatic colorectal cancer (mCRC)
Presenter: Kai Ou
Session: Poster Display
Resources:
Abstract
114P - The prognostic role of LAG-3 expression in metastatic colorectal cancer
Presenter: Yi-Hsuan Huang
Session: Poster Display
Resources:
Abstract
115P - Sidedness and survival of chemo-refractory metastatic colorectal cancer treated with lonsurf or regorafenib: A nationwide population-based study in Taiwan
Presenter: Meng-Che Hsieh
Session: Poster Display
Resources:
Abstract
116P - Burden and trends of colorectal cancer in high income Asia Pacific countries from 1990-2019 and its projections of deaths to 2040: A comparative analysis
Presenter: Monika Chhayani
Session: Poster Display
Resources:
Abstract
117P - Australasian real-world treatment selection and clinical outcomes for patients with left side (LS), RAS wildtype (RASwt) metastatic colorectal cancer (mCRC)
Presenter: Vanessa Wong
Session: Poster Display
Resources:
Abstract
119P - Neoadjuvant chemoradiotherapy in the mode of hypofractionation in locally advanced rectal cancer: Is it time to change standards of care?
Presenter: Abror Abdujapparov
Session: Poster Display
Resources:
Abstract
120P - Improved clinical outcomes with cetuximab maintenance therapy in left-sided RAS/BRAF wild-type metastatic colorectal cancer: A real-world study of Hunan cancer hospital
Presenter: Xiaolin Yang
Session: Poster Display
Resources:
Abstract
121P - Single-cell sequencing reveals the role of Treg cells with high expression of BIRC3 in regulating the progression of colorectal cancer
Presenter: Yuqiu Xu
Session: Poster Display
Resources:
Abstract